Latest News
Edwards Lifesciences reports positive two-year data for EVOQUE valve system
30 March 2026 - Structural heart innovation company Edwards Lifesciences (NYSE: EW) on Monday reported new two-year data from its TRISCEND II randomised trial demonstrating sustained clinical benefits for its EVOQUE transcatheter tricuspid valve repl...
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics
30 March 2026 - Belfast-based contract research organisation Fusion Antibodies plc (AIM: FAB) reported on Monday that it has entered into an intellectual property transfer agreement with Finn Therapeutics Ltd, granting the client ownership of certain...
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
30 March 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that China's National Medical Products Administration has accepted for review a new drug application for bepirovirsen, an investigational antisense olig...
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
30 March 2026 - Cardiothoracic imaging software provider 4DMedical Limited (ASX: 4DX) declared on Monday that it has received CE Mark certification for its CT:VQ imaging technology, enabling commercial deployment across the European Union, as the com...
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
30 March 2026 - Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), a biopharmaceutical company focused on autoimmune diseases, announced on Monday that it has entered into a definitive merger agreement to acquire Kezar Life Sciences Inc (NASDAQ:KZR), a biote...